HF
DSGN icon

HRT Financial’s Design Therapeutics DSGN Stock Holding History

HRT Financial’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-31,903
Closed -$240K – 3345
2025
Q3 		$240K Buy
+31,903
New +$160K ﹤0.01% 2319
2024
Q1 		– Sell
-40,718
Closed -$107K – 2487
2023
Q4 		$107K Buy
+40,718
New +$93.3K ﹤0.01% 1880
2023
Q3 		– Sell
-95,264
Closed -$600K – 2550
2023
Q2 		$600K Sell
95,264
-29,699
-24% -$182K 0.01% 1261
2023
Q1 		$721K Buy
+124,963
New +$935K 0.01% 1141
2022
Q3 		– Sell
-40,523
Closed -$567K – 2969
2022
Q2 		$567K Buy
+40,523
New +$547K 0.01% 1394

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

HRT Financial's DSGN Position: Q4 2025 in Review

HRT Financial sold out of Design Therapeutics (DSGN) in Q4 2025, closing a stake of 31,903 shares — an estimated $240K sold.

HRT Financial first reported a position in DSGN in Q2 2022 and held it in 5 quarters. The position peaked at $721K in Q1 2023. 117 funds tracked by Wall St. Rank hold DSGN as of Q4 2025.

  • HRT Financial reported no remaining Design Therapeutics position as of Q4 2025 after selling out during the quarter.
  • HRT Financial sold 31,903 Design Therapeutics shares in Q4 2025, an estimated $240K.
  • HRT Financial first reported a position in Design Therapeutics in Q2 2022 and held it in 5 quarters.
  • HRT Financial's Design Therapeutics position peaked at $721K in Q1 2023.
  • 117 funds tracked by Wall St. Rank held Design Therapeutics as of Q4 2025.

Based on HRT Financial's 13F filing for Q4 2025, filed 12 Feb 2026.